Latest Insider Transactions at Biomarin Pharmaceutical Inc (BMRN)
This section provides a real-time view of insider transactions for Biomarin Pharmaceutical Inc (BMRN). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of BIOMARIN PHARMACEUTICAL INC to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of BIOMARIN PHARMACEUTICAL INC's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Apr 29
2022
|
Jeffrey Robert Ajer EVP, Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
340
+0.61%
|
$21,080
$62.41 P/Share
|
|
Apr 29
2022
|
Jean Jacques Bienaime Director |
BUY
Grant, award, or other acquisition
|
Direct |
341
+0.1%
|
$21,142
$62.41 P/Share
|
|
Apr 29
2022
|
Brian Mueller EVP, Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
340
+0.87%
|
$21,080
$62.41 P/Share
|
|
Apr 29
2022
|
Charles Greg Guyer EVP, Chief Technical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
243
+0.46%
|
$15,066
$62.41 P/Share
|
|
Apr 29
2022
|
George Eric Davis EVP, Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
341
+0.51%
|
$21,142
$62.41 P/Share
|
|
Apr 29
2022
|
Jean Jacques Bienaime Director |
SELL
Open market or private sale
|
Direct |
5,000
-1.47%
|
$405,000
$81.95 P/Share
|
|
Apr 29
2022
|
Jean Jacques Bienaime Director |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+1.45%
|
$185,000
$37.46 P/Share
|
|
Apr 28
2022
|
Jean Jacques Bienaime Director |
SELL
Open market or private sale
|
Direct |
20,000
-5.63%
|
$1,660,000
$83.79 P/Share
|
|
Apr 28
2022
|
Jean Jacques Bienaime Director |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+5.33%
|
$740,000
$37.46 P/Share
|
|
Apr 25
2022
|
George Eric Davis EVP, Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,669
+3.89%
|
$98,753
$37.46 P/Share
|
|
Apr 18
2022
|
Jean Jacques Bienaime Director |
SELL
Open market or private sale
|
Direct |
20,000
-5.63%
|
$1,620,000
$81.91 P/Share
|
|
Apr 18
2022
|
Jean Jacques Bienaime Director |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+5.33%
|
$740,000
$37.46 P/Share
|
|
Apr 14
2022
|
V Bryan Lawlis Director |
SELL
Open market or private sale
|
Direct |
4,250
-15.06%
|
$352,750
$83.66 P/Share
|
|
Apr 14
2022
|
V Bryan Lawlis Director |
BUY
Exercise of conversion of derivative security
|
Direct |
4,250
+13.09%
|
$157,250
$37.46 P/Share
|
|
Apr 14
2022
|
Jean Jacques Bienaime Director |
SELL
Open market or private sale
|
Direct |
10,000
-2.9%
|
$830,000
$83.66 P/Share
|
|
Apr 14
2022
|
Jean Jacques Bienaime Director |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+2.82%
|
$370,000
$37.46 P/Share
|
|
Apr 13
2022
|
Jeffrey Robert Ajer EVP, Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
1,180
-2.1%
|
$96,760
$82.47 P/Share
|
|
Mar 30
2022
|
Jeffrey Robert Ajer EVP, Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
1,381
-2.4%
|
$109,099
$79.56 P/Share
|
|
Mar 29
2022
|
Jeffrey Robert Ajer EVP, Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
1,618
-2.73%
|
$127,822
$79.43 P/Share
|
|
Mar 23
2022
|
Jeffrey Robert Ajer EVP, Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
6,129
-9.37%
|
$496,449
$81.78 P/Share
|
|
Mar 22
2022
|
Jeffrey Robert Ajer EVP, Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
2,073
-3.07%
|
$167,913
$81.0 P/Share
|
|
Mar 21
2022
|
George Eric Davis EVP, Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
6,129
-8.82%
|
$496,449
$81.29 P/Share
|
|
Mar 16
2022
|
Jeffrey Robert Ajer EVP, Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,287
-1.87%
|
$102,960
$80.72 P/Share
|
|
Mar 16
2022
|
Jean Jacques Bienaime Director |
SELL
Payment of exercise price or tax liability
|
Direct |
5,560
-1.63%
|
$444,800
$80.72 P/Share
|
|
Mar 16
2022
|
George Eric Davis EVP, Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,252
-1.77%
|
$100,160
$80.72 P/Share
|
|
Mar 16
2022
|
Brian Mueller EVP, Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
582
-1.5%
|
$46,560
$80.72 P/Share
|
|
Mar 16
2022
|
Henry J Fuchs President, Worldwide R&D |
SELL
Payment of exercise price or tax liability
|
Direct |
2,259
-1.55%
|
$180,720
$80.72 P/Share
|
|
Mar 15
2022
|
Jeffrey Robert Ajer EVP, Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
8,418
-10.91%
|
$656,604
$78.27 P/Share
|
|
Mar 15
2022
|
Jeffrey Robert Ajer EVP, Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
11,940
+13.4%
|
-
|
|
Mar 15
2022
|
Jean Jacques Bienaime Director |
SELL
Payment of exercise price or tax liability
|
Direct |
38,306
-10.11%
|
$2,987,868
$78.27 P/Share
|
|
Mar 15
2022
|
Jean Jacques Bienaime Director |
BUY
Grant, award, or other acquisition
|
Direct |
40,280
+9.61%
|
-
|
|
Mar 15
2022
|
George Eric Davis EVP, Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
8,290
-10.49%
|
$646,620
$78.27 P/Share
|
|
Mar 15
2022
|
George Eric Davis EVP, Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
11,040
+12.26%
|
-
|
|
Mar 15
2022
|
Charles Greg Guyer EVP, Chief Technical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
920
-1.74%
|
$71,760
$78.27 P/Share
|
|
Mar 15
2022
|
Charles Greg Guyer EVP, Chief Technical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
11,040
+17.25%
|
-
|
|
Mar 15
2022
|
Brian Mueller EVP, Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,868
-4.58%
|
$145,704
$78.27 P/Share
|
|
Mar 15
2022
|
Brian Mueller EVP, Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
11,040
+21.32%
|
-
|
|
Mar 15
2022
|
Henry J Fuchs President, Worldwide R&D |
SELL
Payment of exercise price or tax liability
|
Direct |
12,101
-7.65%
|
$943,878
$78.27 P/Share
|
|
Mar 15
2022
|
Henry J Fuchs President, Worldwide R&D |
BUY
Grant, award, or other acquisition
|
Direct |
38,790
+19.7%
|
-
|
|
Mar 11
2022
|
Jean Jacques Bienaime Director |
SELL
Open market or private sale
|
Direct |
15,000
-4.24%
|
$1,155,000
$77.81 P/Share
|
|
Mar 11
2022
|
Jean Jacques Bienaime Director |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+4.07%
|
$555,000
$37.46 P/Share
|
|
Mar 10
2022
|
Jean Jacques Bienaime Director |
SELL
Open market or private sale
|
Direct |
15,000
-4.24%
|
$1,155,000
$77.57 P/Share
|
|
Mar 10
2022
|
Jean Jacques Bienaime Director |
BUY
Exercise of conversion of derivative security
|
Direct |
15,000
+4.07%
|
$555,000
$37.46 P/Share
|
|
Mar 08
2022
|
Jeffrey Robert Ajer EVP, Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
9,370
+12.56%
|
-
|
|
Mar 08
2022
|
George Eric Davis EVP, Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
9,370
+12.12%
|
-
|
|
Mar 08
2022
|
Henry J Fuchs President, Worldwide R&D |
BUY
Grant, award, or other acquisition
|
Direct |
12,840
+9.72%
|
-
|
|
Mar 08
2022
|
Jean Jacques Bienaime Director |
BUY
Grant, award, or other acquisition
|
Direct |
34,780
+9.32%
|
-
|
|
Feb 28
2022
|
Dennis Slamon Director |
SELL
Open market or private sale
|
Direct |
6,396
-3.9%
|
$498,888
$78.35 P/Share
|
|
Feb 25
2022
|
Elaine J Heron Director |
BUY
Exercise of conversion of derivative security
|
Direct |
8,500
+9.54%
|
$314,500
$37.46 P/Share
|
|
Feb 03
2022
|
Brian Mueller EVP, Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,072
-3.48%
|
$93,264
$87.77 P/Share
|